{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:14:13Z","timestamp":1790910853835,"version":"4.1.0"},"reference-count":75,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,2,15]]},"abstract":"<jats:p> PURPOSE: To evaluate interactions between expressions of tumor suppressor gene p53 and angiogenic factors vascular endothelial cell growth factor (VEGF) and interleukin-8 (IL-8) and their effect on tumor angiogenesis and patient prognosis in non\u2013small-cell lung cancer (NSCLC). <\/jats:p><jats:p> PATIENTS AND METHODS: p53, VEGF, IL-8, and the microvessel endothelium were immunostained, and VEGF and IL-8 mRNA expression were quantified using the real-time quantitative reverse-transcription polymerase chain reaction in 65 NSCLC surgical specimens. Aberrant p53 expression was correlated with VEGF and IL-8 mRNA expression, microvessel count (MVC), other clinical-pathologic variables, and patients\u2019 survival. <\/jats:p><jats:p> RESULTS: Tumors with high aberrant p53 expression showed significantly higher VEGF and IL-8 mRNA expression and MVC than those with low aberrant p53 expression (P &lt; .001). When tested as a continuous variable, aberrant p53 expression correlated strongly and positively with VEGF and IL-8 mRNA expression and MVC (P &lt; .0001). Tumors with high aberrant p53 expression were associated with mediastinal or distant lymph node metastasis (P = .006). Survival and postoperative relapse time were significantly shorter in patients with high aberrant p53 expression tumors than in those with low aberrant expression tumors (P &lt; .0001). A significant difference in survival was also seen between patients with high and low tumoral VEGF mRNA expression and between those with high and low tumoral IL-8 mRNA expression (P &lt; .0001). <\/jats:p><jats:p> CONCLUSION: We report here for the first time that aberrant p53 expression is strongly positively correlated with VEGF mRNA and IL-8 mRNA expression in NSCLC. This result indicates that aberrant p53 expression may play a significant role in regulation of VEGF and IL-8 expression and be involved in controlling angiogenesis and explains the adverse prognosis of cancers with high aberrant p53 expression. <\/jats:p>","DOI":"10.1200\/jco.2002.20.4.900","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T08:46:55Z","timestamp":1487926015000},"page":"900-910","source":"Crossref","is-referenced-by-count":12,"title":["Aberrant <i>p53<\/i> Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1200","volume":"20","author":[{"given":"Ang","family":"Yuan","sequence":"first","affiliation":[{"name":"From the Division of Chest Medicine, Department of Internal Medicine; Division of Chest Surgery, Department of Surgery; and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, and Institute of Biomedical Sciences, Academia Sinica, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[{"name":"From the Division of Chest Medicine, Department of Internal Medicine; Division of Chest Surgery, Department of Surgery; and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, and Institute of Biomedical Sciences, Academia Sinica, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwen-Tay","family":"Luh","sequence":"additional","affiliation":[{"name":"From the Division of Chest Medicine, Department of Internal Medicine; Division of Chest Surgery, Department of Surgery; and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, and Institute of Biomedical Sciences, Academia Sinica, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sow-Hsong","family":"Kuo","sequence":"additional","affiliation":[{"name":"From the Division of Chest Medicine, Department of Internal Medicine; Division of Chest Surgery, Department of Surgery; and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, and Institute of Biomedical Sciences, Academia Sinica, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Chie","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Division of Chest Medicine, Department of Internal Medicine; Division of Chest Surgery, Department of Surgery; and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, and Institute of Biomedical Sciences, Academia Sinica, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[{"name":"From the Division of Chest Medicine, Department of Internal Medicine; Division of Chest Surgery, Department of Surgery; and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, and Institute of Biomedical Sciences, Academia Sinica, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-103606","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.1.4"},{"key":"R2-103606","doi-asserted-by":"publisher","DOI":"10.1038\/339058a0"},{"key":"R3-103606","unstructured":"Srivastava  A,   Laidler  P,   Davises  RP,  et al:   The prognostic significance of tumor vascularity in intermediate-thickness (0.766-4.0 mm thick) skin melanoma:  A quantitative histologic study.   Am J Pathol 133:  419,1988-423,"},{"key":"R4-103606","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240101"},{"key":"R5-103606","unstructured":"Weidner  N,   Carroll  PR,   Flax  J,  et al:   Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.  Am J Pathol 143:  401,1993-409,"},{"key":"R6-103606","doi-asserted-by":"crossref","unstructured":"Li  VW,   Folkert  RD,   Watanabe  H,  et al:   Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors.  Lancet 334:  82,1994-86,","DOI":"10.1016\/S0140-6736(94)91280-7"},{"key":"R7-103606","doi-asserted-by":"publisher","DOI":"10.1007\/BF02052599"},{"key":"R8-103606","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93150-L"},{"key":"R9-103606","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.6.8520790"},{"key":"R10-103606","doi-asserted-by":"publisher","DOI":"10.1038\/nm0195-27"},{"key":"R11-103606","doi-asserted-by":"publisher","DOI":"10.1038\/359845a0"},{"key":"R12-103606","doi-asserted-by":"crossref","unstructured":"Plate  KH,   Breier  G,   Weich  HA,  et al:   Vascular endothelial growth factor and glioma angiogenesis:  Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanism.   Int J Cancer 59:  529,1994-529,","DOI":"10.1002\/ijc.2910590415"},{"key":"R13-103606","unstructured":"Takahashi  Y,   Kitadai  Y,   Bucana  CD,  et al:   Expression of vascular endothelial growth factor and its receptor:  KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.   Cancer Res 55:  3964,1995-3968,"},{"key":"R14-103606","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1994.tb02904.x"},{"key":"R15-103606","doi-asserted-by":"crossref","unstructured":"Mattern  J,   Koomagi  R,   Volm  M:   Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinoma.  Int J Cancer 6:  1059,1995-1062,","DOI":"10.3892\/ijo.6.5.1059"},{"key":"R16-103606","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A"},{"key":"R17-103606","unstructured":"Brown  LF,   Berse  B,   Jackman  RW,  et al:   Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.  Am J Pathol 143:  1255,1993-1262,"},{"key":"R18-103606","unstructured":"Fontanini  G,   Vignati  S,   Boldrini  L,  et al:   Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.  Clin Cancer Res 3:  861,1997-865,"},{"key":"R19-103606","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I"},{"key":"R20-103606","unstructured":"Luca  M,   Huang  S,   Gershenwald  JE,  et al:   Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis.  Am J Pathol 151:  1105,1997-1113,"},{"key":"R21-103606","doi-asserted-by":"publisher","DOI":"10.1007\/BF02361238"},{"key":"R22-103606","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.8.1201"},{"key":"R23-103606","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.5.1409"},{"key":"R24-103606","doi-asserted-by":"publisher","DOI":"10.1126\/science.1905840"},{"key":"R25-103606","doi-asserted-by":"crossref","unstructured":"Deb  S,   Jackson  CT,   Subler  MA,  et al:   Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.  J Virol 66:  6164,1992-6170,","DOI":"10.1128\/jvi.66.10.6164-6170.1992"},{"key":"R26-103606","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90421-8"},{"key":"R27-103606","unstructured":"Quinlan  DC,   Davidson  AS,   Summers  CL,  et al:   Accumulation of p53 correlates with a poor prognosis in human lung cancers.  Cancer Res 53:  4828,1992-4831,"},{"key":"R28-103606","doi-asserted-by":"publisher","DOI":"10.1126\/science.7521539"},{"key":"R29-103606","unstructured":"Kieser  A,   Weich  HA,   Brandner  G,  et al:   Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.  Oncogene 9:  963,1994-969,"},{"key":"R30-103606","unstructured":"Mukhopadhyay  D,   Tsiokas  L,   Sukhatme  VP:   Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.  Cancer Res 55:  6161,1995-6165,"},{"key":"R31-103606","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<502::AID-IJC4>3.0.CO;2-7"},{"key":"R32-103606","doi-asserted-by":"publisher","DOI":"10.1159\/000011918"},{"key":"R33-103606","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10145-9"},{"key":"R34-103606","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.51.10.771"},{"key":"R35-103606","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.470"},{"key":"R36-103606","unstructured":"Agani  F,   Kirsch  DG,   Griedman  SL,  et al:   p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene.  Cancer Res 57:  4474,1997-4477,"},{"key":"R37-103606","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/77.2.123"},{"key":"R38-103606","doi-asserted-by":"publisher","DOI":"10.1378\/chest.89.4_Supplement.225S"},{"key":"R39-103606","doi-asserted-by":"publisher","DOI":"10.1038\/3327"},{"key":"R40-103606","doi-asserted-by":"crossref","unstructured":"Bieche  I,   Onody  P,   Laurendeau  I,  et al:   Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.  Clin Chem 45:  1148,1999-1156,","DOI":"10.1093\/clinchem\/45.8.1148"},{"key":"R41-103606","doi-asserted-by":"crossref","unstructured":"Ferrara  N,   Houck  K,   Jakeman  L,  et al:   Molecular and biological properties of the vascular endothelial-growth-factor family of proteins.  Endocr Res 13:  8,1992-31,","DOI":"10.1210\/edrv-13-1-18"},{"key":"R42-103606","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114265"},{"key":"R43-103606","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/12.3.1687"},{"key":"R45-103606","doi-asserted-by":"crossref","unstructured":"Kaplan  EL,   Meier  P:   Nonparametric estimation from incomplete observations.  J Am Stat Assoc 53:  457,1956-481,","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R46-103606","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-199905000-00002"},{"key":"R47-103606","unstructured":"Rak  J,   Mitsuhashi  Y,   Bayko  L,  et al:   Mutant ras oncogenes upregulate VEGF\/VPF expression:  Implications for induction and inhibition of tumor angiogenesis.   Cancer Res 55:  4575,1995-4580,"},{"key":"R48-103606","unstructured":"Giatromanolaki  A,   Koukourakis  MI,   Kakolyris  S,  et al:   Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.  Clin Cancer Res 4:  3017,1998-3024,"},{"key":"R49-103606","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.22.9979"},{"key":"R50-103606","doi-asserted-by":"publisher","DOI":"10.1038\/363281a0"},{"key":"R51-103606","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(96)00039-1"},{"key":"R52-103606","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00677-1"},{"key":"R53-103606","unstructured":"Bardessey  N,   Bechwith  JB,   Pelletier  J:   Clonal expression and attenuated apoptosis in Wilms\u2019 tumors are associated with p53 gene mutations.  Cancer Res 55:  215,1995-219,"},{"key":"R54-103606","doi-asserted-by":"publisher","DOI":"10.1038\/358015a0"},{"key":"R55-103606","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb08279.x"},{"key":"R56-103606","doi-asserted-by":"crossref","unstructured":"Bosari  S,   Viale  G:   The clinical significance of p53 aberrations in human tumors.  Virchows Arch 427:  229,1995-241,","DOI":"10.1007\/BF00203389"},{"key":"R57-103606","unstructured":"Van Oijen MGCT,    Slootweg  PF:   Gain-of-function mutations in the tumor suppressor gene p53.  Clin Cancer Res 6:  2138,2000-2145,"},{"key":"R58-103606","unstructured":"Smith  ML,   Chen  IT,   Zhan  Q,  et al:   Involvement of the p53 tumor suppressor in repair of u.v.type DNA damage.  Oncogene 10:  1053,1995-1059,"},{"key":"R59-103606","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.v5.i1.20"},{"key":"R60-103606","doi-asserted-by":"publisher","DOI":"10.1101\/gr.1.3.199"},{"key":"R61-103606","unstructured":"Sigal  A,   Rotter  V:   Oncogenic mutation of the p53 tumor suppressor:  the demons of the guardian of the genome.   Cancer Res 60:  6788,2000-6793,"},{"key":"R62-103606","unstructured":"Iwamoto  KS,   Mizuno  T,   Ito  T,  et al:   Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival.  Cancer Res 56:  3862,1996-3865,"},{"key":"R63-103606","unstructured":"Shaulsky  G,   Goldfinger  N,   Rotter  V:   Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.  Cancer Res 51:  5232,1991-5237,"},{"key":"R64-103606","unstructured":"Hsiao  M,   Low  J,   Dorn  E,  et al:   Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.  Am J Pathol 145:  702,1994-714,"},{"key":"R65-103606","unstructured":"Lin  J,   Teresky  AK,   Levine  AJ:   Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutation.  Oncogene 10:  2387,1995-2390,"},{"key":"R66-103606","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.7.3735"},{"key":"R67-103606","doi-asserted-by":"crossref","unstructured":"Carbone  DP,   Mitsudomi  T,   Chiba  I,  et al:   p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer:  A preliminary report of LCSG 871.   Chest 106:  377s,1994-381s,     (suppl 6)","DOI":"10.1378\/chest.106.6.377S"},{"key":"R68-103606","unstructured":"Rusch  V,   Klimstra  D,   Linkov  I,  et al:   Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development.  Cancer Res 55:  1365,1995-1372,"},{"key":"R69-103606","unstructured":"Ebina  M,   Steinberg  SM,   Mulshine  JL,  et al:   Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.  Cancer Res 54:  2496,1994-2503,"},{"key":"R70-103606","unstructured":"Harpole  DH,   Herndon  JE,   Wolfe  WG,  et al:   A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.  Cancer Res 55:  51,1995-56,"},{"key":"R71-103606","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.220"},{"key":"R72-103606","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(98)00937-0"},{"key":"R73-103606","unstructured":"Tormanen  U,   Eerola  AK,   Rainio  P,  et al:   Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma.  Cancer Res 55:  5595,1995-5602,"},{"key":"R74-103606","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.24.2018"},{"key":"R75-103606","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1893"},{"key":"R76-103606","doi-asserted-by":"crossref","unstructured":"Ferrer  FA,   Miller  LJ,   Andrawis  RI,  et al:   Angiogenesis and prostate cancer:  In vivo and in vitro expression of angiogenesis factors by prostate cancer cells.   Urology 51:  161,1998-167,","DOI":"10.1016\/S0090-4295(97)00491-3"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.20.4.900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:55:30Z","timestamp":1653515730000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.20.4.900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,15]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,2,15]]}},"alternative-id":["10.1200\/JCO.2002.20.4.900"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.20.4.900","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,15]]}}}